CUPERTINO, Calif., Aug. 26, 2020 /PRNewswire/ -- DURECT Corporation
(Nasdaq: DRRX) announced today that James
E. Brown, President, CEO, Michael H.
Arenberg, Chief Financial Officer and Dr. WeiQi Lin, Executive Vice President of R&D
will be participating in a fireside chat hosted by Ellie Merle of Cantor Fitzgerald, tomorrow,
Thursday, August 27, 2020 at
11:00 a.m. EDT / 8:00 a.m. PDT.
A live webcast of the presentation will be available by
accessing
https://us02web.zoom.us/webinar/register/WN_rrEeQAs1SDKasS-4FKHDRQ
The live webcast of the presentation will also be available
by accessing DURECT's homepage at www.durect.com and clicking
on the "Investors" tab.
About DURECT Corporation
DURECT is a biopharmaceutical company committed to transforming
the treatment of acute organ injury and chronic liver diseases by
advancing novel and potentially lifesaving therapies based on its
endogenous epigenetic regulator program. DURECT's lead candidate,
DUR-928 is an endogenous sulfated oxysterol and an epigenetic
regulator. It represents a new class of therapeutics with a unique
mechanism of action. DUR-928 epigenetically modulates the
expression of multiple clusters of master genes that are involved
in many important cell signaling pathways, through which it
stabilizes mitochondria, reduces lipotoxicity, regulates
inflammatory or stress responses, and promotes cell survival. This
drug candidate is currently in Phase 2 development for the
treatment of alcoholic hepatitis (AH) and the treatment of COVID-19
patients with acute liver or kidney injury as well as Phase 1
development for the treatment of nonalcoholic steatohepatitis
(NASH). DURECT's proprietary drug delivery technologies are
designed to enable new indications and enhanced attributes for
small-molecule and biologic drugs. One late-stage product candidate
in this category is POSIMIR® (bupivacaine
extended-release solution), an investigational locally-acting,
non-opioid analgesic intended to provide up to three days of
continuous pain relief after surgery. For more information about
DURECT, please visit www.durect.com and follow us on Twitter
https://twitter.com/DURECTCorp.
DURECT Forward-Looking Statement
The statements in
this press release regarding the potential for DUR-928 to treat
patients with AH, NASH, COVID-19, or other acute organ injury and
chronic liver diseases , plans for clinical development of DUR-928
and the potential benefits and uses of our drug candidates,
including the potential use of DUR-928 to treat AH, NASH and
COVID-19 patients with acute liver or kidney injury and other acute
and chronic diseases, and the potential of POSIMIR to treat
post-surgical pain are forward-looking statements involving risks
and uncertainties that can cause actual results to differ
materially from those in such forward-looking statements. Potential
risks and uncertainties include, but are not limited to, the risks
that future clinical trials of DUR-928 do not confirm the results
of trials conducted on small numbers of patients, are not started
or finalized when anticipated, take longer to conduct than
anticipated, do not generate similar positive results as generated
in earlier clinical or pre-clinical trials, or do not demonstrate
the safety or efficacy of DUR-928 in a statistically significant
manner, the risk of disruptions to our business operations
resulting from the COVID-19 pandemic, the risk that additional time
and resources may be required for development, testing and
regulatory approval of DUR-928, potential adverse effects arising
from the testing or use of our drug candidates, the potential that
the FDA will not approve POSIMIR, our potential failure to maintain
our collaborative agreements with third parties or consummate new
collaborations and risks related to our ability to obtain capital
to fund operations and expenses. Further information regarding
these and other risks is included in DURECT's Form 10-Q filed on
August 4, 2020 under the heading
"Risk Factors."
NOTE: POSIMIR® and SABER® are trademarks
of DURECT Corporation. Other referenced trademarks belong to
their respective owners. DUR-928 and POSIMIR are
investigational drug candidates under development and have not been
approved for commercialization by the U.S. Food and Drug
Administration or other health authorities for any indication.
SOURCE:
DURECT Corporation
View original
content:http://www.prnewswire.com/news-releases/durect-corporation-fireside-chat-hosted-by-ellie-merle-of-cantor-fitzgerald-301119226.html
SOURCE DURECT Corporation